Psychiatry

Back to articles

Memantine First Agent Approved in U.S. for Severe Alzheimer’s Disease

KEY POINT

FDA has approved memantine (Namenda—Forest), an uncompetitive (open channel) N-methyl-D-asparate (NMDA) antagonist, for treatment of moderate to severe Alzheimer’s disease (AD).

SOURCES

Namenda Web site http://www.namenda.com Reisberg B et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333–41. 

Reisberg B et al.  Memantine in moderate-to-severe Alzheimer's disease.  N Engl J Med.  2003;348;1333-41.

Farlow MR et al. Neurology. 2003;60(suppl 1):A412.